PIR International's 2023 EU/UK biotech board remuneration and diversity study

We are delighted to announce the launch of PIR International’s 2023 EU/UK Biotech Board Remuneration and Diversity Study.

Last year we embarked on producing one of the first dedicated studies which was independent and sourced directly from biotech board members and c-suite executives across the EU and UK. In this year’s exercise we are splitting our focus in to separate board and c-suite studies to engage each cohort independently, allowing us to dive deeper and give our audience greater insights on board trends, behaviours and makeup whilst capturing important data on remuneration and diversity in parallel.

This year’s board study was greeted by a strong response, giving us the ability to create an insightful report thanks to participation from board profiles and industry commentators across the European and UK biotechnology sector. To access the report, register on our website (www.pir-intl.com). We hope you find the report insightful and compelling.

Steve Bates OBE, CEO of BIA, said: “The UK Bioindustry Association welcomes the continued focus on diversity, equity and inclusion across the innovative life sciences and biotech sector in the UK, as evidenced by this report. It's encouraging that the PIR International’s EU & UK Board Remuneration and Diversity findings indicate that the industry is moving, albeit slowly, in the right direction. As our own BIA's Diversity and Inclusion in UK Biotech report shows recognising the gaps is crucial because it helps our sector remain committed to addressing them and making meaningful change.

BIA is taking concrete steps to support member companies in advancing diversity and inclusion in their own organisations with initiatives like BIA’s Women in Biotech programme and a series of Diversity, Equity, and Inclusion (DEI) workshops. 

For the UK and European life sciences and biotech sector to thrive, we need to attract and nurture talented innovators from diverse backgrounds. This will take a sustained collaborative effort. By ensuring that diversity and inclusion remain priorities in the biotech and life sciences sector, the industry can continue to flourish and contribute positively to society and the global economy.”

On diversity, data shows that out of 183 boards that took part in the EU & UK Board Remuneration and Diversity report, 25% have female board members, which is slightly more than last year. Similarly, BIA’s survey of 30 biotech companies with over 1,200 employees, shows that at the executive or founder level women account for 31.5% of C-suite roles and 26% of CEOs.

68% of those Board members studied believe that there is a distinct imbalance in ethnic representation on Biotech boards in the EU/UK. Only 4% have board members with a racial and ethnic minority background. According to data from the BIA’s Diversity and Inclusion report, 19.6 of respondents identified as members of racial or ethnic minorities and less than 15% of those are C-suite. For chief executives, the figure is 11 per cent; none are women from Black or minority ethnic backgrounds.


More news and updates 

Stablepharma secures Innovate UK grant, bridge funding round to launch

This joint Innovate UK grant will advance the clinical development of Stablepharma’s lead candidate, SPVX02, a fridge-free vaccine for the prevention of Tetanus and Diphtheria, validating its safety and efficacy through first-in-human clinical trials.

Broken String Biosciences closes $15 million Series A funding round

Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design,  has closed a $15 million Series A investment round.

CPI launches RNA Centre of Excellence

UK's first RNA therapeutic innovation center opens in Darlington, driving cutting-edge vaccine and therapeutic development.

UK rare disease research landscape mapped for first time

A detailed view of rare disease research in the UK has been captured for the first time in a new report published today. It reveals over £1.1 billion has been invested by Government and charities over a five-year-period.

Life Science Group: A finalist for the Innovate UK KTP Awards 2023

Life Science Group (LSG) proudly announces its selection as a finalist in the Impact and Transformation Award category of the esteemed 2023 Innovate UK Knowledge Transfer Partnership (KTP) Best of the Best Awards.

Advancing early lung cancer diagnosis

Life Science Group are delighted to be part of a consortium, led by Welsh scientists at Aberystwyth University, to develop a novel and potentially disruptive lateral flow device for the detection of early-stage lung cancer.

Accelerating innovation in cell culture solutions through collaborative funding

Life Science Group Ltd (LSG) is excited to announce that its joint application with the Mary Lyon Centre (MLC) at MRC Harwell to the MRC National Mouse Genetics Network (NMGN) Business Engagement Fund has been approved in principle, pending the signature of the relevant agreements.

FDA grants US Orphan Drug Designation to Medannex's MDX-124

Medannex Ltd announced today that its novel therapy, MDX-124, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA).

AlveoGene launches to develop inhaled gene therapies for rare respiratory disorders

New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC)

AstraZeneca commits £100 million to advance UK energy efficiency

15-year agreement with Future Biogas will provide 100 GWh of green gas (biomethane) annually, equivalent to meet the heat demands of over 8,000 homes


More within